Collate

Collate is a San Francisco-based company that builds large language model applications to automate documentation work in the life sciences industry, covering regulatory filings, clinical trial documentation, quality management and product development paperwork for diagnostic, medical device, drug development, pharmaceutical and biotech organizations. The company positions its platform as an AI-native enterprise system intended to shorten the path from concept to commercial market by digitizing compliance workflows.

The product targets the volume problem in life sciences submissions, which can run to roughly 10,000 pages and historically require months of specialist effort. The company reports time savings of 50% to 90%, stating that a document that previously took about seven months may be completed in a month or less. Collate says its accuracy is above 90% and often closer to 97%, and it requires human verification before any document is exported from its system or submitted to a regulator such as the FDA.

Collate was founded by Surbhi Sarna (CEO), Nate Smith (CTO) and Jigish Patel (Chief Architect and Security Officer). Its technical leadership includes staff previously at NVIDIA, Amazon/AWS AI, Hippocratic AI, PicnicHealth, ArsenalBio, Apple, Google, Facebook and TikTok.

Founding story

Surbhi Sarna previously founded nVision Medical, an ovarian cancer early-detection company she started after her own experience as a patient with painful ovarian cysts; nVision was acquired by Boston Scientific for $275 million in 2018. She describes encountering continual paperwork burdens at every stage of that company, from R&D through clinical, marketing and sales. After nVision she became a partner at Y Combinator leading its healthcare practice, where she says she saw the capabilities of modern software and AI and concluded the life sciences industry should be freed from repetitive documentation work. She left YC to start Collate, saying the opportunity could only be pursued by someone who had lived the documentation problem and also understood AI. Co-founder Nate Smith, a former YC visiting partner who had co-founded and led the recruiting platform Lever (acquired by Employ for $517 million), joined after an informal conversation with Sarna; Jigish Patel, a SaaS and cloud infrastructure architect formerly at Netflix, Airbnb, Symantec and VeriSign, is the third founder.

Business model

Enterprise software sold to life sciences organizations. Investor Satish Dharmaraj characterized the motion at the seed stage as low-velocity, high-contract-value selling that is sticky, with the expectation of landing large pharmaceutical accounts and expanding within them.

Sources describe enterprise accounts and high-contract-value sales to life sciences companies; no pricing or revenue figures are disclosed.

Traction

First customer signed in May 2025; approximately 50 enterprise customers by June 2026, including large pharmaceutical companies, major medical device manufacturers and publicly traded biotech firms. Valuation approaching $1 billion with $125 million raised in total.

Latest developments

In June 2026 Collate announced a $95 million round led by Redpoint Ventures at a valuation approaching $1 billion, with prior investors First Round Capital and Conviction Partners. Stated uses of proceeds include scaling engineering capacity, accelerating product development, and expanding enterprise sales internationally. Planned product expansion covers end-to-end clinical trial data management, automated quality management systems, and multi-jurisdictional compliance translation for European and Asian regulatory regimes.